UAE-Based BioSapien Secures $7 Million to Advance Cancer Treatment
BioSapien works to advance its 3D-printed drug delivery tech, aiming to treat over a million patients by 2035.
Jan 28, 2025
BioSapien, a biotech startup with operations in both the UAE and the US, has extended its pre-Series A funding to $7 million, attracting new investment from Golden Gate Ventures' MENA Fund. This marks the fund's inaugural investment in the region. The extended round follows an initial $5.5 million raise in December, led by Global Ventures, with additional participation from Dara Holdings.
Founded in 2018 by Khatija Ali, BioSapien has developed MediChip, a 3D-printed drug delivery platform that targets cancer cells with precision while minimising the systemic side effects of conventional treatments. The funds raised will be used to expedite clinical trials in the UAE, scheduled to begin in Q2 2025, and to scale product development and manufacturing.
MediChip's technology delivers medications directly to tumours, reducing the amount of drugs required without compromising effectiveness. Initially focused on treating colorectal cancer, the startup plans to expand its platform to address other cancers, including pancreatic and lung cancers, as well as non-cancer applications like hormone therapy and biologics. BioSapien aims to treat over one million patients by 2035.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CairoScene
23-05-2025
- CairoScene
UAE's Tarjama Raises $15M to Scale Its Arabic-Focused AI Platform
Backed by Global Ventures and Wamda, Tarjama will expand its Arabic AI systems and launch an AI academy targeting enterprise use. May 23, 2025 UAE-based language technology firm Tarjama has secured $15 million in a Series A funding round to grow its proprietary Arabic-first artificial intelligence platform. The round was led by Global Ventures with support from Wamda Capital, TA Ventures, Phaze Capital, Golden Gate Ventures, and Endeavor Catalyst. Founded in 2009, Tarjama develops tools for machine translation, transcription, and content generation in over 50 languages, including 22 Arabic dialects. With the new capital, the company will scale its engineering team, upgrade its infrastructure, and launch an AI Academy to support talent development in the region. At the core of Tarjama's push is Pronoia V2, a large language model designed to outperform existing global AI systems on Arabic-language tasks. Built for enterprise use, Pronoia V2 supports applications in legal, government, and media sectors, among others. Tarjama currently serves over 700 clients across more than 30 global markets. This investment comes amid growing efforts in the Middle East to develop Arabic-native AI infrastructure. While global language models often underperform in Arabic due to data scarcity and linguistic complexity, regional startups like Tarjama are looking to bridge this gap with purpose-built models. Countries such as the UAE and Saudi Arabia have prioritised Arabic AI in their national tech strategies, with initiatives such as Falcon LLM and Noor LLM reflecting a broader push to ensure the language is meaningfully represented in the AI era.
CairoScene
23-02-2025
- CairoScene
Oman Investment Authority Joins $100M Singapore Fund to Boost Startups
As part of the partnership, Golden Gate Ventures plans to establish an office in Oman. Feb 23, 2025 Oman's startup ecosystem is getting a $100 million push from Singapore, with the Oman Investment Authority (OIA) announcing its investment in Golden Gate Ventures. The deal is expected to drive foreign investment, support Omani entrepreneurs, and open doors for new technology hubs in the region. The Singaporean fund, founded in 2011, has backed over 100 companies across Asia, the US and Europe, including nine that reached billion-dollar valuations. It has already invested in Omani data analytics company Bayanat, signaling its interest in the region's tech sector. As part of the partnership, Golden Gate Ventures plans to establish an office in Oman, aiming to strengthen ties with local startups and investors while providing funding for early-stage companies. The move could connect Omani businesses with Southeast Asia's fast-growing tech markets, offering access to capital and expertise. The investment is part of OIA's Generations Portfolio, which manages foreign assets across multiple industries. The authority has been expanding its focus on future-driven sectors such as artificial intelligence, renewable energy and digital technology.
CairoScene
28-01-2025
- CairoScene
UAE-Based BioSapien Secures $7 Million to Advance Cancer Treatment
BioSapien works to advance its 3D-printed drug delivery tech, aiming to treat over a million patients by 2035. Jan 28, 2025 BioSapien, a biotech startup with operations in both the UAE and the US, has extended its pre-Series A funding to $7 million, attracting new investment from Golden Gate Ventures' MENA Fund. This marks the fund's inaugural investment in the region. The extended round follows an initial $5.5 million raise in December, led by Global Ventures, with additional participation from Dara Holdings. Founded in 2018 by Khatija Ali, BioSapien has developed MediChip, a 3D-printed drug delivery platform that targets cancer cells with precision while minimising the systemic side effects of conventional treatments. The funds raised will be used to expedite clinical trials in the UAE, scheduled to begin in Q2 2025, and to scale product development and manufacturing. MediChip's technology delivers medications directly to tumours, reducing the amount of drugs required without compromising effectiveness. Initially focused on treating colorectal cancer, the startup plans to expand its platform to address other cancers, including pancreatic and lung cancers, as well as non-cancer applications like hormone therapy and biologics. BioSapien aims to treat over one million patients by 2035.
